SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Technology Stocks : Stock Swap -- Ignore unavailable to you. Want to Upgrade?


To: Grashopper who wrote (17190)1/16/2001 1:27:03 PM
From: Tech Master  Respond to of 17305
 
I've been watching the volume spiking... but I don't have an explanation yet...



To: Grashopper who wrote (17190)1/24/2001 10:12:13 AM
From: Tech Master  Respond to of 17305
 
Another old favorite showing real promise:

Celsion Is Developing 'Smart Bomb' Cancer Drugs to Target Tumors Using MIT and Duke Technologies

Goal Is to Commercialize Temperature-Sensitive Liposomes to Target Tumors with Cancer Drugs

COLUMBIA, Md., Jan. 24 /PRNewswire/ -- Celsion Corporation (Amex: CLN - news), headquartered in Columbia, Maryland, announced today that it will enter the pharmaceutical field by pursuing the development of temperature-sensitive, drug-laden liposomes for use with its ``focused heat systems'' to target pros- tate, liver, ovarian and other cancers. Celsion will undertake this develop- ment using exclusive licenses from Massachusetts Institute of Technology (``MIT'') for its' ``Smart Bomb'' Adaptive Phased Array (``APA'') focused heat tech- nology and from Duke University to commercialize its' temperature-sensitive liposomes.

On March 1, August 15, and December 15, 2000, Duke researchers published three separate scientific articles in the journal Cancer Research explaining the scientific merit and clinical potential of using Duke's patent pending temperature-sensitive liposome in combination with Celsion's focused heat sys- tem to achieve targeted drug delivery for cancer treatment.

The pre-clinical data summarized in the Duke publications indicates that Duke's temperature-sensitive liposomes release their drugs in tumors in sec- onds (compared with hours using conventional liposomes). Thus, there was an increase in drug concentration in the tumors treated with Duke's liposomes of 30 to 50 times that of conventional liposomes. As a result, 11 out of 11 mice treated with temperature-sensitive liposomes had 100% remission of their cancerous tumors.

Celsion has contracted with a liposome and drug formulation and manufac- turing facility in Canada for production of an initial batch of temperature- sensitive, drug-laden liposomes. This initial batch is sufficient to conduct several large animal toxicity studies as well as a Phase I clinical feasibil- ity demonstration using up to 30 patients. Celsion has signed an agreement with Dartmouth University to conduct a large animal toxicity study to assess safety. That study is expected to begin early in 2001.

Upon successful completion of the large animal toxicity evaluations, Cel- sion plans to file several investigational new drug applications (INDs) with the Food and Drug Administration (FDA) to begin clinical evaluation of heat- activated liposome drug delivery in patients for treatment of prostate, liver and ovarian cancer. Celsion has an agreement with Duke University for patient evaluations and is in negotiations to add several other cancer research insti- tutions as additional investigative sites.

Dr. Augustine Cheung, Celsion's founder, Chairman and Chief Scientific Of- ficer stated, ``I am hopeful that these developments will enable Celsion to evolve, beyond its current scope of using heat alone to treat Benign Prostatic Hyperplasia and breast cancer, and establish its business as a mainstream can- cer treatment company. It is envisioned that in the future the Company will use heat, both alone and in combination with other drugs encapsulated in its temperature-sensitive liposomes, to treat a broad range of cancers and other conditions.''

About Celsion: Celsion Corporation, a Russell 3000 company based in Colum- bia, Maryland, is a research and development company dedicated to commercial- izing medical treatment systems for cancer and other diseases using focused heat technology delivered by patented microwave technology. Celsion has re- search, license or commercialization agreements with leading institutions such as Duke University Medical Center, Massachusetts Institute of Technology, Har- bor UCLA Medical Center, the University of California at San Francisco, the Center for Breast Surgery at Columbia Hospital in Florida, Montefiore Medical Center, Memorial Sloan Kettering Cancer Center in New York and Duke Univer- sity. For more information on Celsion, visit our website: celsion.com.

Forward-looking statements in this release are made pursuant to the ``safe harbor'' provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials; possible changes in cost and timing of development and testing, capital structure, and other financial items; changes in approaches to medical treatment; introduc- tion of new products by others; possible acquisitions of other technologies, assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Com- pany's periodic reports filed with the Securities and Exchange Commission.

For Further Information Contact:
John Mon
Celsion Corporation
410.290.5390
john@celsion.com

Geoffrey Eiten
Natl. Financial Network
888.399.7541 (ext. 613)
geiten@nfnonline.com

Ira Weingarten/Steve Henricks
Equity Communications
888.530.7051
equity@silcom.com

SOURCE: Celsion Corporation



To: Grashopper who wrote (17190)1/26/2001 9:29:26 AM
From: Tech Master  Respond to of 17305
 
Re: IRSN

Talk about adding DoD muscle to your Board...

Friday January 26, 5:58 am Eastern Time

Press Release

SOURCE: iNetWorks Corporation

William Perry & John Deutch Join iNetWorks Board

COSTA MESA, Calif., Jan. 26 /PRNewswire/ -- iNetWorks(TM) Corporation, a subsidiary of Irvine Sensors Corporation (Nasdaq: IRSN, BSE: ISC), today announced the appointment of Dr. William J. Perry and Dr. John M. Deutch to its Board of Directors.

Dr. Perry, former United States Secretary of Defense, is presently a professor at Stanford University, with a joint appointment in the School of Engineering and the Institute for International Studies, and also serves on the board of Cylink and several emerging companies. Dr. Perry's prior business experience includes serving as a laboratory director for General Telephone and Electronics (1954-1964); founding and serving as the president of ESL, Inc. (1964-1977); Executive Vice-President of Hambrecht & Quist, Inc. (1981-1985); and founding and serving as the Chairman of Technology Strategies & Alliances (1985-1993). Dr. Perry received his B.S. and M.S. from Stanford University and his Ph.D. from Penn State, all in mathematics. He is a member of the National Academy of Engineering and a fellow of the American Academy of Arts and Sciences.

Dr. Deutch, presently an Institute Professor at the Massachusetts Institute of Technology, is a former Deputy Secretary of Defense and Director of Central Intelligence. He has served as Dean of Science and Provost of M.I.T. Dr. Deutch earned a B.A. in history and economics from Amherst College and both his B.S. in chemical engineering and Ph.D. in physical chemistry from M.I.T. He holds honorary degrees from Amherst College, University of Lowell and Northeastern University. Dr. Deutch also serves as director for Ariad Pharmaceutical, Citicorp, CMS Energy, Cummins, Raytheon, and Schlumberger Ltd., all publicly traded companies.

Mel R. Brashears, Chairman and Chief Executive Officer of iNetWorks, noted, ``Bill Perry and John Deutch have uniquely broad backgrounds that are relevant to the technologies, businesses, financing and scope of what iNetWorks has set out to accomplish. We understand the magnitude of the business challenge associated with the explosive growth of telecommunications networks and the Internet, and we also understand the corresponding magnitude of the rewards that can come with success. We have actively sought the kind of outside Directors that can help us address those challenges and achieve that success. We believe that Bill Perry and John Deutch are precisely those kinds of individuals. Having worked with both previously, we enthusiastically look forward to their contribution.''

iNetWorks is developing a telecommunications router product for potential introduction in 2002 that combines Irvine Sensor's patented 3-dimensional (3D) chip-stacking and interconnect structures with superconducting electronics, providing 100 times the throughput of what is available today. iNetWorks is presently co-located with its parent, Irvine Sensors Corporation, in Costa Mesa, California.

Irvine Sensors Corporation is primarily engaged in the development of high density electronics, MicroElectroMechanical sensors (MEMS) and readout circuits, miniature cameras, electro-optical and optical switches, image processing devices and software, electronic image stabilization, wireless infrared communications products, and low-power analog and mixed-signal integrated circuits for diverse systems applications. It primarily seeks to commercialize its technologies through independently financed and managed subsidiaries.

Except for historical information contained herein, the matters set forth in this news release are forward-looking statements that are dependent on risks and uncertainties including such factors, among others, as the market risks associated with new products, the impact of competitive technologies and the pace at which new markets develop. Further information on Irvine Sensors Corporation and its subsidiaries, including, iNetWorks Corporation, is contained in publicly-filed disclosures available through the SEC's EDGAR database (www.sec.gov) or from the Company's Investor Relations.

SOURCE: iNetWorks Corporation